196 related articles for article (PubMed ID: 11328410)
1. The growth factor receptors HER-2/neu and EGFR, their relationship, and their effects on the prognosis in early stage (FIGO I-II) epithelial ovarian carcinoma.
Skirnisdóttir I; Sorbe B; Seidal T
Int J Gynecol Cancer; 2001; 11(2):119-29. PubMed ID: 11328410
[TBL] [Abstract][Full Text] [Related]
2. P53, bcl-2, and bax: their relationship and effect on prognosis in early stage epithelial ovarian carcinoma.
Skirnisdóttir I; Sorbe B; Seidal T
Int J Gynecol Cancer; 2001; 11(2):147-58. PubMed ID: 11328414
[TBL] [Abstract][Full Text] [Related]
3. A new prognostic model comprising p53, EGFR, and tumor grade in early stage epithelial ovarian carcinoma and avoiding the problem of inaccurate surgical staging.
Skírnisdóttir I; Seidal T; Sorbe B
Int J Gynecol Cancer; 2004; 14(2):259-70. PubMed ID: 15086725
[TBL] [Abstract][Full Text] [Related]
4. Overexpression and relationships of HER-2/neu, epidermal growth factor receptor, p53, Ki-67, and tumor necrosis factor alpha in epithelial ovarian cancer.
Goff BA; Shy K; Greer BE; Muntz HG; Skelly M; Gown AM
Eur J Gynaecol Oncol; 1996; 17(6):487-92. PubMed ID: 8971524
[TBL] [Abstract][Full Text] [Related]
5. The prognostic importance of p53, bcl-2, and bax in early stage epithelial ovarian carcinoma treated with adjuvant chemotherapy.
Skirnisdóttir I; Seidal T; Gerdin E; Sorbe B
Int J Gynecol Cancer; 2002; 12(3):265-76. PubMed ID: 12060448
[TBL] [Abstract][Full Text] [Related]
6. Prognostic impact of concomitant p53 and PTEN on outcome in early stage (FIGO I-II) epithelial ovarian cancer.
Skírnisdóttir I; Seidal T
Int J Gynecol Cancer; 2011 Aug; 21(6):1024-31. PubMed ID: 21792012
[TBL] [Abstract][Full Text] [Related]
7. Prevalence and significance of HER-2/neu expression in early epithelial ovarian cancer.
Rubin SC; Finstad CL; Federici MG; Scheiner L; Lloyd KO; Hoskins WJ
Cancer; 1994 Mar; 73(5):1456-9. PubMed ID: 7906607
[TBL] [Abstract][Full Text] [Related]
8. Effect of HER-2/neu overexpression on chemoresistance and prognosis in ovarian carcinoma.
Sasaki N; Kudoh K; Kita T; Tsuda H; Furuya K; Kikuchi Y
J Obstet Gynaecol Res; 2007 Feb; 33(1):17-23. PubMed ID: 17212661
[TBL] [Abstract][Full Text] [Related]
9. Is adjuvant radiotherapy in early stages (FIGO I-II) of epithelial ovarian cancer a treatment of the past?
Skirnisdottir I; Nordqvist S; Sorbe B
Oncol Rep; 2005 Aug; 14(2):521-9. PubMed ID: 16012740
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of p53, Her-2, and EGFR overexpression in borderline and epithelial ovarian cancer.
Nielsen JS; Jakobsen E; Hølund B; Bertelsen K; Jakobsen A
Int J Gynecol Cancer; 2004; 14(6):1086-96. PubMed ID: 15571614
[TBL] [Abstract][Full Text] [Related]
11. Activation of c-erbB-2 and prognosis in ovarian carcinoma. Comparison with histologic type, grade, and stage.
Singleton TP; Perrone T; Oakley G; Niehans GA; Carson L; Cha SS; Strickler JG
Cancer; 1994 Mar; 73(5):1460-6. PubMed ID: 7906608
[TBL] [Abstract][Full Text] [Related]
12. Assessment of Her-1, Her-2, And Her-3 expression and Her-2 amplification in advanced stage ovarian carcinoma.
Lee CH; Huntsman DG; Cheang MC; Parker RL; Brown L; Hoskins P; Miller D; Gilks CB
Int J Gynecol Pathol; 2005 Apr; 24(2):147-52. PubMed ID: 15782071
[TBL] [Abstract][Full Text] [Related]
13. Cyclooxygenase-2 (COX-2), epidermal growth factor receptor (EGFR), and Her-2/neu expression in ovarian cancer.
Ferrandina G; Ranelletti FO; Lauriola L; Fanfani F; Legge F; Mottolese M; Nicotra MR; Natali PG; Zakut VH; Scambia G
Gynecol Oncol; 2002 May; 85(2):305-10. PubMed ID: 11972392
[TBL] [Abstract][Full Text] [Related]
14. HER-2/neu expression is associated with high tumor cell proliferation and aggressive phenotype in a population based patient series of endometrial carcinomas.
Engelsen IB; Stefansson IM; Beroukhim R; Sellers WR; Meyerson M; Akslen LA; Salvesen HB
Int J Oncol; 2008 Feb; 32(2):307-16. PubMed ID: 18202752
[TBL] [Abstract][Full Text] [Related]
15. Multivariate survival analysis of clinicopathologic features in surgical stage I endometrioid carcinoma including analysis of HER-2/neu expression.
Nazeer T; Ballouk F; Malfetano JH; Figge H; Ambros RA
Am J Obstet Gynecol; 1995 Dec; 173(6):1829-34. PubMed ID: 8610771
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical localization of c-erbB-2 protein and epidermal growth factor receptor in normal surface epithelium, surface inclusion cysts, and common epithelial tumours of the ovary.
Wang DP; Konishi I; Koshiyama M; Nanbu Y; Iwai T; Nonogaki H; Mori T; Fujii S
Virchows Arch A Pathol Anat Histopathol; 1992; 421(5):393-400. PubMed ID: 1360720
[TBL] [Abstract][Full Text] [Related]
17. Overexpression of epithelial macrophage colony-stimulating factor (CSF-1) and CSF-1 receptor: a poor prognostic factor in epithelial ovarian cancer, contrasted with a protective effect of stromal CSF-1.
Chambers SK; Kacinski BM; Ivins CM; Carcangiu ML
Clin Cancer Res; 1997 Jun; 3(6):999-1007. PubMed ID: 9815777
[TBL] [Abstract][Full Text] [Related]
18. Clinical utility of determination of HER-2/neu and EGFR fragments in serum of patients with metastatic breast cancer.
Witzel I; Thomssen C; Krenkel S; Wilczak W; Bubenheim M; Pantel K; Neumann R; Jänicke F; Müller V
Int J Biol Markers; 2006; 21(3):131-40. PubMed ID: 17013794
[TBL] [Abstract][Full Text] [Related]
19. The ErbB signalling pathway: protein expression and prognostic value in epithelial ovarian cancer.
de Graeff P; Crijns AP; Ten Hoor KA; Klip HG; Hollema H; Oien K; Bartlett JM; Wisman GB; de Bock GH; de Vries EG; de Jong S; van der Zee AG
Br J Cancer; 2008 Jul; 99(2):341-9. PubMed ID: 18628764
[TBL] [Abstract][Full Text] [Related]
20. Clinical significance of growth factor receptor EGFR and angiogenesis regulator VEGF‑R2 in patients with ovarian cancer at FIGO stages I-II.
Skirnisdottir I; Åkerud H; Seidal T
Int J Oncol; 2018 Oct; 53(4):1633-1642. PubMed ID: 30066848
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
